First Half 2026 Recap: Dermatology

The beginning of 2026 represents a notable period in dermatology, with dermatologists seeing a wide array of clinical guidance releases, major regulatory approvals, and promising advances across the inflammatory skin disease spectrum. Some notable stories were covered by the HCPLive editorial team, including the US Food and Drug Administration (FDA) approval of the first new sunscreen active ingredient in decades, a novel oral IL-23 inhibitor for psoriasis, and new options for young children with plaque psoriasis.